Mr. Michael Sosnowik RPh, PD
President, MSS Consultants, LLC
Member of the Healthcare Council
Council Member Biography
Michael Sosnowik, PD, Pharmacist and former C-Level executive in pharma distribution, is the President of MSS Consultants, an independent consulting firm to pharmaceutical manufacturers, distributors as well as managed care providers, in New York, since September 2007. Previously, Mr. Sosnowik was the Chief Executive Officer of LAB123. He has held upper level management positions in retail pharmacy, institutional and managed care pharmacies, and the wholesale trade. Mr. Sosnowick's experience includes membership on formulary, pharmacy and therapeutics committees as well as day to day operational responsibility. He has also served as the President of QK Healthcare. (This is me - Update Profile)
Employment History
- 2007 - 2007
- President, Giant
- 2007 - Unspecified
- President, MSS Consultants, LLC
- 2006 - 2007
- President and Chief Executive Officer, LAB 123, Inc.
- 1995 - 2005
- President, QK HEALTHCARE, INC
GLG NewsSM Analyses by Michael Sosnowik
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
June 19, 2007
'Pill Splitting' Cuts Drug Costs for Patients, Health Plans | www.forbes.com
The article glossed over issues such as pharmacist/pharmacy involvement, tablet scoring, and narrow thereapeutic range drugs, all of which can can profound impact into this practice.
-
June 7, 2007
DexCom Receives FDA Approval For 7-Day STS Continuous Glucose Monitoring System | www.medicaldesignonline.com
cost ease of use
-
June 7, 2007
FDA Clears Wyeth Contraceptive Pill | online.wsj.com
-side effect profile -3rd party reimbursement -patient cost
-
June 7, 2007
FDA Clears Wyeth Contraceptive Pill | online.wsj.com
The side effect profile and impact will be the key indicator whether this product is as successful as it can be.
GLG Study Groups with Michael Sosnowik(?)
| Study Group Name | No. Members |
|---|---|
| Generic Drug Economic Experts | 890 |
| Economic Experts on Managed Care | 804 |
| Oncology Reimbursement Experts (US) | 182 |
| Generic Pharmaceuticals Regulation Experts: Healthcare Consultants | 57 |
GLG Live Meetings with Michael Sosnowik(?)
Michael Sosnowik has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.